Foghorn Therapeutics Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Foghorn Therapeutics Inc.
Merck & Co. will pay Seattle Genetics $725m up front in cash under the two deals and make a $1bn equity investment in the company, providing financial flexibility to broadly fund the pipeline.
The company previously cut 2020 revenue expectations by $2.5bn, including $1.7bn for pharma products. Keytruda’s dominance and portfolio diversification also may dominate second quarter call.
The pandemic is expected to dominate the industry's second quarter earnings calls, which kick off on 16 July, but here are 10 other topics to listen for.
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.